External References
Last updated on: 10/18/2024
The following sources were used as references for this guide's content.
Cytokine Release Syndrome (CRS)
- Cytokine release syndrome
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- With New Bispecific Antibodies in Multiple Myeloma, Nurses Need To Know How to Manage CRS
ICANS
- Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
- CAR T-Cell Grading and Management: ICANS
- In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
- Management of ICANS Associated with Bispecific Antibodies in MM
Infection Prevention
- Prophylaxis - Pneumocystis jirovecii (carinii) pneumonia in cancer patients
- Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
- Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
- Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia
IVIG
- Is IVIG treatment medically necessary or medically beneficial?
- Intravenous Immunoglobulin (IVIG)
- Potential Subcutaneous IG therapy
Teclistamab
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
- Support & Savings | TECVAYLI® (teclistamab-cqyv)
Elranatamab
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
- ELREXFIO.com
- Navigating Support & Financial Resources
- Your Guide to Understanding ELREXFI
Talquetamab
- Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
- U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
- Support & Resources | TALVEY® (talquetamab-tgvs)
- WHAT YOU SHOULD KNOW ABOUT TALVEY™
Bispecifics in Clinical Trials
- Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
- Bispecific Antibodies in Earlier Lines of Therapy for Patients With Multiple Myeloma: A Bright Future for the New Kids on the Block
High-Risk Myeloma and Bispecifics
- How to Treat High-Risk Myeloma at Diagnosis and Relapse
- First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)